Buserelin vs Triptorelin
A synthetic GnRH agonist that suppresses hormones to help treat prostate cancer, endometriosis, and infertility
GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Buserelin
200–200 mcg
Triptorelin
11.25–11.25 mg
Frequency
Buserelin
Once daily
Triptorelin
Once daily
Administration
Buserelin
Subcutaneous injection
Triptorelin
Intramuscular injection
Cycle length
Buserelin
Ongoing/indefinite
Triptorelin
Ongoing/indefinite
Onset speed
Buserelin
Moderate (1-2 weeks)
Triptorelin
Moderate (1-2 weeks)
Evidence level
Buserelin
Strong human trials (Phase 3 or FDA approved)
Triptorelin
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Hormone Suppression
Cancer Management
Fertility Support
Hormone Regulation
Endometriosis Relief
Compound specifications
Buserelin
Molecular formula
C60H86N16O13
Molecular weight
1239.4 g/mol
Half-life
2-4 hours (subcutaneous), 30-60 minutes (intranasal); longer for depot formulation (28-40 days)
Bioavailability
~1% (oral); ~10-15% (intranasal); ~95% (subcutaneous)
CAS number
57773-65-6
Triptorelin
Molecular formula
C64H82N18O13
Molecular weight
1311.4 g/mol
Half-life
2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)
Bioavailability
~100% (intramuscular/subcutaneous injection)
CAS number
57773-63-4
Dosing compared
Buserelin
Subcutaneous
500 mcg
Every 8 hours (3 times daily) · First 7 days
The product label starts prostate cancer treatment with 500 mcg under the skin every 8 hours for the first week [5].
200 mcg
Once daily · Ongoing maintenance
After the first week, the label switches to 200 mcg once daily under the skin for ongoing treatment [5].
Intranasal
400 mcg (2 sprays per nostril)
3 times daily (1,200 mcg/day) · Ongoing maintenance
The nasal spray option delivers 400 mcg three times a day as maintenance, an alternative to daily injections [5].
Implant
6.3 mg
Once every 2 months · Long-term
A long-acting implant placed under the skin slowly releases buserelin over about 2 months, so no daily dosing is needed [5].
9.45 mg
Once every 3 months · Long-term
A larger implant lasts about 3 months between placements [5].
Triptorelin
Intramuscular injection
3.75 mg
Once every 4 weeks · Ongoing while indicated
FDA-labeled 1-month depot (Trelstar) for advanced prostate cancer; single IM injection into either buttock [5].
11.25 mg
Once every 12 weeks · Ongoing while indicated
FDA-labeled 3-month depot (Trelstar). Strengths are not additive; chosen by desired interval [5].
22.5 mg
Once every 24 weeks · Ongoing while indicated
FDA-labeled 6-month depot (Trelstar for prostate cancer; Triptodur 22.5 mg for central precocious puberty, ages 2+) [5][6].
Best suited for
Buserelin
Managing advanced prostate cancer
Buserelin is particularly well-suited for individuals focused on managing advanced prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Treating endometriosis and reducing associated pain
Buserelin is particularly well-suited for individuals focused on treating endometriosis and reducing associated pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Optimizing ovarian response during fertility treatments
Buserelin is particularly well-suited for individuals focused on optimizing ovarian response during fertility treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Triptorelin
Managing advanced prostate cancer when combined with other treatments
Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving severe endometriosis pain and symptoms
Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Delaying puberty development in children with early sexual maturation
Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety & evidence
Buserelin
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for other use
Safety overview
Buserelin is an FDA-approved GnRH agonist with safety data from Phase 3 trials and decades of clinical use, but carries well-documented risks from intentional testosterone/estrogen suppression. The initial testosterone flare (first 2-3 weeks) can worsen prostate cancer symptoms and cause tumor flare pain in 10-20% of patients. Long-term use causes bone density loss of 2-3% annually, with vertebral fractures in 10-20% of long-term users. Cardiovascular risks include increased MI and stroke in men over 65. Hot flashes affect 40-80%, erectile dysfunction is nearly universal, and liver enzyme elevations occur in 5%. Nasal spray formulation causes local irritation in 20-30% of users.
Contraindications
- Pregnancy or breastfeeding
- Hypersensitivity to GnRH agonists
- Certain bone diseases when long-term use is planned
Triptorelin
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.
Contraindications
- Pregnancy (can affect fetal development)
- Undiagnosed vaginal bleeding
- Known hypersensitivity to GnRH agonists
- Severe untreated depression
- Active spinal cord compression in prostate cancer (requires urgent decompression)
Which is right for you?
Choose Buserelin if...
- Managing advanced prostate cancer
- Treating endometriosis and reducing associated pain
- Optimizing ovarian response during fertility treatments
Choose Triptorelin if...
- Managing advanced prostate cancer when combined with other treatments
- Relieving severe endometriosis pain and symptoms
- Delaying puberty development in children with early sexual maturation